Project Grant R01CA279962
Award Date
9/17/24
Completion Date
8/31/29
Dollars Obligated
$498K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Cincinnati, OH 45221, USA
Similar Awards
This $676,006 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund research to develop non-invasive imaging strategies to identify mechanisms of resistance to cancer immunotherapy early after treatment. The researchers will utilize PET imaging to measure markers of immune response and neutrophil levels, as well as implantable fluorescence sensors to continuously monitor these parameters in vivo. They will pair these molecular...
This Cooperative Agreement, awarded by the National Cancer Institute (NCI) under CFDA Program 93.394 - Cancer Detection and Diagnosis Research, provides $1,453,091 in funding to develop and clinically evaluate an imaging-enabled, adaptable CAR T cell (IMAC) therapy platform. The University of Pennsylvania will lead this project, which aims to create a novel CAR T cell approach that can be monitored and controlled through PET imaging and targeted biologics. The goal is to enable safe and...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports the development of 111In-dinutuximab-IR800, a dual-labeled molecular imaging agent for intraoperative detection of metastatic osteosarcoma. The University of Pittsburgh will optimize manufacturing, conduct pharmacology/toxicology studies, and evaluate the agent's ability to detect osteosarcoma metastases in vivo. The $565,988 award will enable translation of this intraoperative molecular...
The Project Grant award R01CA287491, totaling $720,416, was provided by the National Cancer Institute (NCI) under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The award aims to develop a novel "theranostic" (therapeutic and diagnostic) approach using chimeric antigen receptor (CAR) T-cell therapy for the treatment of neuroendocrine prostate cancer (NEPC). The key products and services to be delivered include: Evaluating the therapeutic efficacy of...
This federal Project Grant award of $513,859, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to develop a novel adoptive cellular therapy platform using hematopoietic stem cells (HSCs) engineered with chimeric antigen receptor (CAR) technology. The goal is to generate a continuously renewing population of CAR-expressing natural killer (NK) cells that can provide long-term, safe, and efficacious anti-cancer immunity. The research aims to...
This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $490,381 to The Pennsylvania State University to develop phase-changing peptide nanoemulsion (NPEP) contrast agents for deep tissue ultrasound imaging of adoptive cellular immunotherapies. The goal is to create NPEP agents that can be rapidly internalized and persist within macrophages, enabling real-time and long-term monitoring of macrophage...
This $249,645 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) will support advanced genetic engineering research to unravel the role of tumor-specific B cells in cancer progression. The research, conducted by The Children's Hospital Corporation (doing business as Boston Children's Hospital), aims to exploit a novel B cell gene editing protocol to rapidly generate tumor-specific B cells that can be used to study their impact on tumor...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is focused on developing a "next-generation" precision adoptive T cell therapy approach to treat pediatric high-grade gliomas. The $474,656 award will fund research to evaluate the safety, efficacy, and immunological effects of this therapy in preclinical models, determine the capacity to isolate and expand antigen-specific T cells from pediatric patients, and conduct a Phase 1...